Marta Figueiredo, PhD, science writer —

Marta holds a biology degree, a master’s in evolutionary and developmental biology, and a PhD in biomedical sciences from the University of Lisbon, Portugal. She was awarded a research scholarship and a PhD scholarship, and her research focused on the role of several signaling pathways in thymus and parathyroid glands embryonic development. She also previously worked as an assistant professor of an annual one-week embryology course at the University of Lisbon’s Faculty of Medicine.

Articles by Marta Figueiredo

Deep Brain Stimulation May Help with MS-associated Tremors

Deep brain stimulation (DBS) effectively reduces tremors in people with multiple sclerosis (MS), but may lead to worsening symptoms and speech problems, according to a review study. While these findings support the use of DBS for treating this common, disabling MS symptom, larger studies using standardized measures of…

MS Patients in UK Now Offered COVID-19 Booster Shots

The U.K.’s National Health Service (NHS) has started its COVID-19 vaccine booster program, offering a third shot — preferably with the Pfizer-BioNTech vaccine — to at-risk populations, including people with multiple sclerosis (MS). The decision follows a recommendation by the country’s Joint Committee on Vaccination and Immunization,…

T. Gondii Parasite May Protect Against Developing MS

Toxoplasmosis, an infection by the parasite Toxoplasma gondii, has a protective effect against the development of multiple sclerosis (MS), according to a review study. Specifically, people who had been infected with the parasite were 32% less likely to develop MS than those who never had toxoplasmosis. While these findings support T. gondii…

MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS

MediciNova is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. “Over the past quarter, we…

Collaboration Explores Therapies for Autoimmune Diseases

Cytocom has joined forces with La Jolla Institute for Immunology (LJI) to discover and develop new immune-modulating therapies targeting toll-like receptors (TLRs) for autoimmune diseases such as multiple sclerosis (MS), cancer, and infectious and chronic inflammatory conditions. TLRs are an important family of protein receptors found at the surface…

Ocrevus Effective in RRMS Patients With Poor Responses to Prior DMTs

Ocrevus (ocrelizumab) safely and effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who responded poorly to other disease-modifying therapies (DMTs), final two-year data from the CHORDS Phase 3b clinical trial show. Notably, these benefits also were observed among patients who enrolled in the study…

Trial Will Test Mavenclad for Advanced Progressive MS

After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm function worsening in adults with progressive multiple sclerosis (MS) and very limited walking abilities, has recruited its first patient. The study, ChariotMS (NCT04695080), aims to…

Risk of Severe COVID-19 Not Raised by Immunosuppressive DMTs

Exposure to multiple sclerosis (MS) disease-modifying therapies (DMTs), and particularly immunosuppressive DMTs, does not increase the risk of developing a severe form of COVID-19, or of dying from the disease, when adjusting for known risk factors, an Austrian registry-based study found. These findings add to data showing no…

Oral CKD-506 Lessens Symptoms, Demyelination in MS Mouse Model

Chong Kun Dang (CKD) Pharmaceutical’s experimental oral therapy CKD-506 suppressed inflammation, myelin loss (demyelination), and lessened symptoms in a mouse model of multiple sclerosis (MS), a study reported. Notably, the therapy resulted in benefits generally comparable to those of Gilenya (fingolimod) in these mice. But it also…

Targeting Ion Channel Piezo1 in T-cells Eased MS in Mice

Removing an ion channel called Piezo1 from immune T-cells lessened disease severity in a mouse model of multiple sclerosis (MS), a study showed. Notably, these beneficial effects were associated with an expansion of regulatory T-cells (Tregs) — a type of immune cell that typically dampens immune and inflammatory responses —…

Kesimpta for RRMS Now Available in Scotland at Low or No Cost

Adults in Scotland with active relapsing-remitting multiple sclerosis (RRMS) will now have access at low or no cost to Kesimpta (ofatumumab), the first self-administered, at-home B-cell-targeting therapy for people with the neurodegenerative disease. The Scottish Medicines Consortium (SMC) recommended that the Novartis therapy be available through the…

Questions to Ask Your Doctor If You’re Newly Diagnosed

Illustration of doctor an patient talked
We consulted some of our community contributors at MS News Today and came up with 12 questions people should consider asking their doctors after an MS diagnosis.

Check it out by clicking here.

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here